Robigo
PrivateLast Round
Series A
Sep 17, 2026
Total Funding Raised
$12.67M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Robigo operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Grant round in September 2025.
Robigo is a biotechnology company that develops precision microbial treatments to improve plant health and recover lost yields.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clean Manufacturing
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Robigo Comparables
Compare Robigo with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| FA Bio | 83% | |
| Ascribe Bio | 82% | |
| Aphea.Bio | 81% |
For institutional investors. Book with your work email.
Robigo Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 17, 2026 | ||||
| Grant | Sep 15, 2025 | ||||
| Accelerator | Jan 9, 2025 | ||||
| Seed | May 4, 2023 | ||||
| Grant | Jun 1, 2022 | ||||
Pre Seed | Nov 5, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Robigo Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SVG Ventures|THRIVE | Accelerator, Series A |
| Good Growth Capital | Seed |
| Climate Capital | Pre Seed |
| Supply Change Capital | Seed |
| First Star Ventures | Seed, Pre Seed |
| Endeavor8 | Seed, Series A |
| Congruent Ventures | Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 17, 2026
Leads by Bayer, Congruent Ventures, and Endeavor8 participated.
- Feb 1, 2026
Named a Technology Pioneer for developing biopesticides with social impact.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesSep 21, 2026
Robigo's Series A funding accelerates its U.S. launch of engineered microbial biopesticides targeting fungal diseases in soybeans and specialty crops, announced in United States on Sep 17th '26.
- receives_financingSep 21, 2026
In Sep '25, Robigo receives $1.25M in NSF Phase II SBIR funding to advance its engineered microbial solution for soybean Sudden Death Syndrome.
For institutional investors. Book with your work email.
Robigo Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Robigo's valuation, stock price, and market status.
Is Robigo a public or private company?
Robigo is a private company.
What is the current stock price of Robigo?
Robigo is a private company, so its shares have no public market price. Caplight tracks Robigo's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Robigo worth (valuation)?
Valuation information for Robigo is not publicly available.
Can I buy Robigo stock?
Robigo shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Robigo's last funding round?
Robigo's most recent funding round was Series A on September 17, 2026.
Who are the main investors in Robigo?
Key investors in Robigo include Congruent Ventures, Leaps by Bayer.
Will Robigo IPO soon?
No public IPO plans have been announced for Robigo.
How can I track Robigo secondary market activity?
Caplight tracks bids, offers, and trades in Robigo's shares on secondary markets.